Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Trials

Fig. 1

From: Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study

Fig. 1

Identification of trials reviewed by the FDA for New Drug Applications with neuropsychiatric indications, 2005–2014. Flow chart depicting the process of selecting efficacy trials conducted to support new neuropsychiatric drugs and reviewed by the FDA for drug approval between 2005 and 2014. Trials can be excluded for satisfying one or more exclusion criteria

Back to article page